Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy vs.

neoadjuvant chemotherapy alone AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical ...

neoadjuvant chemotherapy alone WILMINGTON, Del., March 31, 2025 – AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as ...

Imfinzi plus chemotherapy significantly improved event-free survival in resectable Stage II-IVA gastric and GEJ cancer patients. A strong trend in overall survival benefit was observed, with final ...

In patients with unresectable liver cancer, treatment with Imjudo plus Imfinzi showed better survival outcomes compared with Nexavar. A treatment combination of Imjudo (tremelimumab) and Imfinzi ...

Based on the changes we have seen in immune infiltration into metastatic lesions, I am optimistic that there is a chance that these patients could still have partial or complete responses to this ...

Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues ... seen in immune infiltration into ...

Based on the changes we have seen in immune infiltration into metastatic lesions, I am optimistic that there is a chance that these patients could still have partial or complete responses to this ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive bladder cancer (MIBC). Now, detailed data show exactly how Imfinzi ...

WILMINGTON, Del., September 15, 2024--(BUSINESS WIRE)--Positive results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with chemotherapy ...